As noted earlier, Oppenheimer downgraded Insulet to Perform from Outperform. As reasons for the downgrade, the firm cited the company's lower than expected 2015 guidance and unfavorable product mix. Target to $33 from $39.
Canaccord raised the firm's price target on Insulet to $234 from $226 and keeps a Buy rating on the shares. The firm said they are becoming more bullish given the significant T2 opportunity that they believe could provide a multi-year tailwind for the company.
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSweetgreen (SG) up... To see the rest of the story go to thefly.com. See Story Here